SPARC-mediated regulation of and coupling to the TGFB signaling system
Schematic of SPARC-mediated regulation of and coupling to the TGF-β signaling system. Inset, long-term TGF-β treatment of Mv1Lu cells stimulates their synthesis of SPARC transcript and protein. Conversely, long-term SPARC treatment induces Mv1Lu cells to produce and secrete TGF-β1, presumably leading to enhanced autocrine TGF-β signaling. Dysregulation of this regulatory loop may exacerbate the development and progression of diseases characterized by alterations in tissue remodeling and repair, including cancer. Newly synthesized SPARC is also endowed with the potential to regulate short-term TGF-β signaling. Although it is unknown whether SPARC acts directly on TGF-β (i.e., activation of latent TGF-β complexes; dashed arrow) or its receptors (dashed arrow), these molecules are in fact necessary and required for SPARC to stimulate the TGF-β signaling system. Activation of TGF-β receptors by SPARC stimulates TGF-β–regulated Smads, which translocate into the nucleus to induce or repress TGF-β–responsive genes, ultimately leading to epithelial cell growth arrest. The ability of SPARC to couple to TGF-β signaling is mediated via its EC domain. Alternatively, cells resistant to TGF-β (i.e., loss of TGF-β receptors or Smad inactivation) remain competent to partial growth arrest by SPARC, a response that is not recapitulated by SPARC-EC. Activation of this unknown pathway likely inhibits the expression and activities of cell cycle components (e.g., cyclin A, Rb-like p107, CDK2, and Rb). Although the contribution of TGF-β signaling to regulation of this unknown SPARC pathway remains to be defined (dashed arrow), both systems cooperate to maximally inhibit epithelial cell proliferation by SPARC.